Ryan Bond - Aclarion Chief Officer
| ACON Stock | USD 0.77 0.08 11.59% |
Insider
Ryan Bond is Chief Officer of Aclarion
| Age | 52 |
| Address | 8181 Arista Place, Broomfield, CO, United States, 80021 |
| Phone | 833 275 2266 |
| Web | https://www.aclarion.com |
Ryan Bond Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ryan Bond against Aclarion stock is an integral part of due diligence when investing in Aclarion. Ryan Bond insider activity provides valuable insight into whether Aclarion is net buyers or sellers over its current business cycle. Note, Aclarion insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aclarion'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ryan Bond over a year ago Purchase by Ryan Bond of 20000 shares of Aclarion |
Aclarion Management Efficiency
The company has return on total asset (ROA) of (1.2769) % which means that it has lost $1.2769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.4547) %, meaning that it created substantial loss on money invested by shareholders. Aclarion's management efficiency ratios could be used to measure how well Aclarion manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aclarion's Return On Capital Employed is very stable compared to the past year. As of the 17th of March 2025, Return On Equity is likely to grow to 6.38, while Return On Tangible Assets are likely to drop (3.59). At this time, Aclarion's Net Tangible Assets are very stable compared to the past year. As of the 17th of March 2025, Non Currrent Assets Other is likely to grow to about 121.5 K, while Total Assets are likely to drop about 2.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tyler Danielson | FOXO Technologies | N/A | |
| Michael Vesey | Forian Inc | 62 | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| Jim Grauel | FOXO Technologies | N/A | |
| Jona Raasch | National Research Corp | 65 | |
| Thyagarajan Ramachandran | Healthcare Triangle | 49 | |
| Jon Boumstein | National Research Corp | N/A | |
| Kristi Lane | Healthcare Triangle | N/A | |
| Sudish Mogli | Healthcare Triangle | 55 | |
| Brian Chen | FOXO Technologies | N/A | |
| Daniel Barton | Forian Inc | 59 | |
| Wei Chen | EUDA Health Holdings | 40 | |
| Gregory MS | National Research Corp | N/A | |
| Steven Sabes | FOXO Technologies | 56 | |
| Mark Grove | Forian Inc | N/A | |
| Susan Neo | FOXO Technologies | N/A | |
| David Terrell | Forian Inc | N/A | |
| Adam Dublin | Forian Inc | 59 | |
| Shibu Kizhakevilayil | Healthcare Triangle | 52 | |
| Robert Potashnick | FOXO Technologies | N/A | |
| Max Wygod | Forian Inc | 37 | |
Management Performance
| Return On Equity | -7.45 | ||||
| Return On Asset | -1.28 |
Aclarion Leadership Team
Elected by the shareholders, the Aclarion's board of directors comprises two types of representatives: Aclarion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aclarion. The board's role is to monitor Aclarion's management team and ensure that shareholders' interests are well served. Aclarion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aclarion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey MD, Executive Chairman | ||
| Ryan Bond, Chief Officer | ||
| Brent Ness, President CEO | ||
| John Lorbiecki, Chief Officer |
Aclarion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aclarion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.45 | ||||
| Return On Asset | -1.28 | ||||
| Operating Margin | (89.95) % | ||||
| Current Valuation | 381.86 K | ||||
| Shares Outstanding | 1.02 M | ||||
| Number Of Shares Shorted | 247.1 K | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 15.91 X | ||||
| Revenue | 75.4 K | ||||
| Gross Profit | (34.23 K) |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclarion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Aclarion Stock, please use our How to Invest in Aclarion guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclarion. If investors know Aclarion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclarion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (804.49) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of Aclarion is measured differently than its book value, which is the value of Aclarion that is recorded on the company's balance sheet. Investors also form their own opinion of Aclarion's value that differs from its market value or its book value, called intrinsic value, which is Aclarion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclarion's market value can be influenced by many factors that don't directly affect Aclarion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclarion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclarion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclarion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.